MedPath

A Study to Learn More About How Well BAY 2927088 Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations in the Genes of Human Epidermal Growth Factor Receptor 2 (HER2)

Phase 3
Recruiting
Conditions
Advanced Non-small Cell Lung Cancer
HER2 Mutation
Interventions
Registration Number
NCT06452277
Lead Sponsor
Bayer
Brief Summary

Researchers are looking for a better way to treat people who have advanced non-small cell lung cancer (NSCLC) with specific genetic changes called human epidermal growth factor receptor 2 (HER2) mutations.

Advanced NSCLC is a group of lung cancers that have spread to nearby tissues or to other parts of the body or that are unlikely to be cured or controlled with currently available treatments. HER2 is a protein that helps cells to grow and divide. A damage (also called mutation) to the building plans (genes) for this protein in cancer cells leads to a production of abnormal HER2 and therefore abnormal cell growth and division.

The study treatment, BAY 2927088, is expected to block the mutated HER2 protein which may stop the spread of NSCLC.

The main purpose of this study is to learn how well BAY 2927088 works and how safe it is compared with standard treatment, in participants who have advanced NSCLC with specific genetic changes called HER2 mutations.

The study participants will receive one of the study treatments:

* BAY 2927088 twice every day as a tablet by mouth, or

* Standard treatment in cycles of 21 days via infusion ("drip") into the vein. The treatment will continue for as long as participants benefit from it without any severe side effects or until they or their doctor decide to stop the treatment.

During the study, the doctors and their study team will:

* take imaging scans, including CT, PET, MRI, and X-rays, of different parts of the body to study the spread of cancer

* check the overall health of the participants by performing tests such as blood and urine tests, and checking

* heart health using an electrocardiogram (ECG)

* perform pregnancy tests for women

* ask the participants questions about how they are feeling and what adverse events they are having.

An adverse event is any medical problem that a participant has during a study. Doctors keep track of all adverse events, irrespective if they think it is related or not to the study treatment.

Detailed Description

Not available

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
278
Inclusion Criteria
  • Participant must be ≥18 years of age or over the legal age of consent in countries where that is greater than 18 years at the time of signing the informed consent.
  • Documented histologically or cytologically confirmed locally advanced non-squamous NSCLC, not suitable for definitive therapy or metastatic non-squamous NSCLC at screening (small cell or mixed histologies are excluded) (Stage III-IV NSCLC).
  • Documented activating HER2 mutation in the tyrosine kinase domain (TKD) assessed by tissue molecular test in a CLIA-certified (US sites) or an equally accredited (outside of the US) local laboratory. However, participants may be included at the discretion of the investigator if the laboratory performing the assay is not CLIA or similar certified but the laboratory is locally accredited.
  • No prior systemic therapy for locally advanced or metastatic disease. No prior treatment with a HER2 ex20ins-targeted therapy (e.g. poziotinib, trastuzumab deruxtecan). Participants who received adjuvant or neoadjuvant therapy are eligible if the adjuvant/neoadjuvant therapy was completed at least 12 months prior to the start of screening.
  • Eligible to receive treatment with the selected platinum-based doublet-chemotherapy (i.e. cisplatin/pemetrexed or carboplatin/pemetrexed) and pembrolizumab in accordance with the SmPC/Product Information.
Exclusion Criteria
  • Known history of prior malignancy except if the participant has undergone potentially curative therapy with no evidence of that disease recurrence for five years since initiation of that therapy. Exception: the following cancer types are acceptable within five years if curatively treated or under surveillance:

    • a. in situ cancers of cervix, breast, or skin,
    • b. superficial bladder cancer (Ta, Tis and T1),
    • c. limited-stage prostate cancer,
    • d. basal or squamous cancers of the skin.
  • Tumors with targetable alterations with approved available therapy, with the exception of HER2 mutation in the TKD.

  • Inability to discontinue treatment with chronic systemic corticosteroids. Participants who require intermittent use of bronchodilators, inhaled steroids, or local steroid injections would not be excluded from the study. Replacement therapy (e.g., physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency) is acceptable, provided that the dose is stable for >4 weeks prior to planned start of study intervention.

  • Pre-existing peripheral neuropathy that is Grade ≥2 by CTCAE (v5.0).

  • History of severe hypersensitivity reaction to treatment with a monoclonal antibody.

  • Prior radiotherapy outside of the brain within 21 days of planned start of study intervention. Participants must have recovered from all radiation-related toxicities and not require corticosteroids.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Standard of care (SoC)PembrolizumabParticipants will receive SoC (pembrolizumab in combination with platinum-based chemotherapy, in 21-day cycles per the approved labels) until disease progression per RECIST v1.1, unacceptable toxicity, or until any other withdrawal criteria.
Standard of care (SoC)CisplatinParticipants will receive SoC (pembrolizumab in combination with platinum-based chemotherapy, in 21-day cycles per the approved labels) until disease progression per RECIST v1.1, unacceptable toxicity, or until any other withdrawal criteria.
Standard of care (SoC)CarboplatinParticipants will receive SoC (pembrolizumab in combination with platinum-based chemotherapy, in 21-day cycles per the approved labels) until disease progression per RECIST v1.1, unacceptable toxicity, or until any other withdrawal criteria.
Standard of care (SoC)PemetrexedParticipants will receive SoC (pembrolizumab in combination with platinum-based chemotherapy, in 21-day cycles per the approved labels) until disease progression per RECIST v1.1, unacceptable toxicity, or until any other withdrawal criteria.
BAY2927088BAY2927088Participants will receive BAY2927088 20 mg BID until disease progression per RECIST v1.1, unacceptable toxicity, or until any other withdrawal criteria.
Primary Outcome Measures
NameTimeMethod
Progression free survival (PFS) per RECIST 1.1 as assessed by BICRUp to approximately 2 years

RECIST 1.1 = Response Evaluation Criteria in Solid Tumors, version 1.1; BICR = blinded independent central review (BICR)

Secondary Outcome Measures
NameTimeMethod
Overall survival (OS)Up to approximately 4 years.
Objective response rate (ORR) per RECIST 1.1 as assessed by BICRUp to approximately 4 years

RECIST 1.1 = Response Evaluation Criteria in Solid Tumors, version 1.1; BICR = blinded independent central review (BICR)

Progression free survival (PFS) per RECIST 1.1 as assessed by the investigatorUp to approximately 4 years

RECIST 1.1 = Response Evaluation Criteria in Solid Tumors, version 1.1

Disease control rate (DCR) per RECIST 1.1 as assessed by the investigatorUp to approximately 4 years

RECIST 1.1 = Response Evaluation Criteria in Solid Tumors, version 1.1

Objective Response Rate (ORR) as assessed by the investigatorUp to approximately 4 years
Disease control rate (DCR) per RECIST 1.1 as assessed by BICRUp to approximately 4 years

RECIST 1.1 = Response Evaluation Criteria in Solid Tumors, version 1.1; BICR = blinded independent central review (BICR)

Duration of response (DOR) as assessed by BICRUp to approximately 4 years

BICR = blinded independent central review (BICR)

Adverse events per CTCAE v 5.0 (eg. TEAEs, TESAEs) categorized by severityUp to approximately 4 years

CTCAE = common terminology criteria for adverse events; TEAE = treatment-emergent adverse event; TESAE = treatment-emergent serious adverse event

Duration of response (DOR) as assessed by the investigatorUp to approximately 4 years
Change from baseline in NSCLC-SAQ total scoreUp to approximately 4 years

NSCLC-SAQ = Non-small cell lung cancer Symptom Assessment Questionnaire

Change from baseline in NSCLC-SAQ individual domain scoresUp to approximately 4 years

NSCLC-SAQ = Non-small cell lung cancer Symptom Assessment Questionnaire; Domains: cough, pain, dyspnea, fatigue, appetite

Time to deterioration in NSCLC-SAQ total scoreUp to approximately 4 years

NSCLC-SAQ = Non-small cell lung cancer Symptom Assessment Questionnaire

Time to deterioration in NSCLC-SAQ individual domain scoresUp to approximately 4 years

NSCLC-SAQ = Non-small cell lung cancer Symptom Assessment Questionnaire; Domains: cough, pain, dyspnea, fatigue, appetite

Time to deterioration in EORTC QLQ-C30 physical functioning domain scoreUp to approximately 4 years

EORTC QLQ-C30: European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30

Change from baseline in EORTC QLQ-C30 physical functioning domain scoreUp to approximately 4 years

EORTC QLQ-C30: European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30; QoL: quality of life

Change from baseline in EORTC QLQ-C30 global health status/QoLUp to approximately 4 years

EORTC QLQ-C30: European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30; QoL: quality of life

Trial Locations

Locations (267)

Memorial Cancer Institute at Miramar

🇺🇸

Miramar, Florida, United States

Allegheny General Hospital

🇺🇸

Pittsburgh, Pennsylvania, United States

MHAT Sveta Marina EAD

🇧🇬

Varna, Bulgaria

Docrates Mehiläinen Syöpäsairaala

🇫🇮

Helsinki, Finland

Institut Bergonie - Unicancer Nouvelle Aquitaine

🇫🇷

Bordeaux, France

Hopital Foch - Oncologie digestive et thoracique

🇫🇷

Suresnes, France

Gustave Roussy - Departement Oncologie-Radiotherapie

🇫🇷

Villejuif Cedex, France

Centre Hospitalier Intercommunal Creteil - Service de pneumologie

🇫🇷

Créteil, France

Institut de Cancerologie Ouest - Saint-Herblain

🇫🇷

Saint-Herblain, France

Centro Hospitalar e Universitario de Coimbra EPE (CHUC)

🇵🇹

Coimbra, Portugal

Patty & George Hoag Cancer Center

🇺🇸

Newport Beach, California, United States

Hospital Universitrio Dr. José Eleuterio González. Servicio de Oncologia

🇲🇽

Nuevo León, Mexico

Rivne regional antitumor hospital

🇺🇦

Rivne, Ukraine

UC San Diego Health - Moores Cancer Center

🇺🇸

San Diego, California, United States

University of California San Francisco (UCSF) - Thoracic Surgery and Oncology Clinic

🇺🇸

San Francisco, California, United States

Velindre University NHS Trust | Velindre Cancer Centre - Clinical Trials Unit

🇬🇧

Cardiff, United Kingdom

Hospital Ramón y Cajal | Oncología

🇪🇸

Madrid, Spain

Fundacion Jimenez Diaz (Clinica de la Concepcion)

🇪🇸

Madrid, Spain

Complejo Hospitalario de Navarra

🇪🇸

Pamplona, Spain

Medical Center LLC "Verum Expert Clinic"

🇺🇦

Kyiv, Ukraine

Brampton Civic Hospital - Oncology

🇨🇦

Brampton, Ontario, Canada

The Canberra Hospital (TCH) - Canberra Region Cancer Centre (CRCC)

🇦🇺

Garran, Australia

ASST Sette Laghi_Ospedale Macchi - Oncologia

🇮🇹

Varese, Italy

Austin Hospital - Olivia Newton John Cancer Research Institute

🇦🇺

Heidelberg, Australia

Volyn Regional Oncology Center

🇺🇦

Lutsk, Ukraine

Uniklinikum Salzburg, Universitätsklinik für Innere Medizin III

🇦🇹

Salzburg, Austria

Uniklinikum Salzburg, Universitätsklinik für Pneumologie/ Lungenheilkunde

🇦🇹

Salzburg, Austria

Centro Ricerche Cliniche Di Verona S.r.l. - Oncologia

🇮🇹

Verona, Italy

Hospital Clinic de Barcelona (Hospital Clinic i Provincial)

🇪🇸

Barcelona, Spain

Medizinische Universität Wien Universitätsklinik f. Innere Medizin I Klinische Abteilung für Onkologie

🇦🇹

Wien, Austria

Klinik Floridsdorf, Pneumo-onkologische Ambulanz und Tagesklinik

🇦🇹

Wien, Austria

University of California Los Angeles (UCLA) - Cancer Care - Santa Monica

🇺🇸

Santa Monica, California, United States

The Oncology Institute of Hope and Innovation

🇺🇸

Whittier, California, United States

AdventHealth Cancer Institute

🇺🇸

Orlando, Florida, United States

Moffitt Cancer Center

🇺🇸

Tampa, Florida, United States

University of Illinois at Chicago

🇺🇸

Chicago, Illinois, United States

The U Chicago Medicine Comprehensive Cancer Center

🇺🇸

Chicago, Illinois, United States

Specialized Hospital for Active Treatment of Oncology

🇧🇬

Sofia, Bulgaria

University of Maryland

🇺🇸

Baltimore, Maryland, United States

UMass Memorial Medical Center - University Campus

🇺🇸

Worcester, Massachusetts, United States

Profound Research LLC

🇺🇸

Farmington Hills, Michigan, United States

University of Minnesota Medical Center

🇺🇸

Minneapolis, Minnesota, United States

Northwell Health Cancer Institute - R.J. Zuckerberg Cancer Center (Monter Cancer Center) - Center for Advanced Medicine Location

🇺🇸

New Hyde Park, New York, United States

University of Cincinnati Medical Center

🇺🇸

Cincinnati, Ohio, United States

Providence Cancer Institute - Franz Clinic

🇺🇸

Portland, Oregon, United States

UT Southwestern

🇺🇸

Dallas, Texas, United States

University of Texas MD Anderson Cancer Center

🇺🇸

Houston, Texas, United States

Fundación Cenit para la Investigación en Neurociencias

🇦🇷

Caba, Ciudad Auton. De Buenos Aires, Argentina

Hospital Italiano de Buenos Aires

🇦🇷

Buenos Aires, Argentina

Centro de Educacion Medica e Investigaciones Clinicas "Norberto Quirno" (CEMIC)

🇦🇷

Buenos Aires, Argentina

Centro Médico Privado CEMAIC

🇦🇷

Córdoba, Argentina

Instituto Argentino de Diagnostico y Tratamiento (IADT)

🇦🇷

TBC, Argentina

Centro de Investigaciones Clínicas, Clínica Viedma

🇦🇷

Viedma, Argentina

Blacktown Cancer & Haematology Centre

🇦🇺

Blacktown, New South Wales, Australia

Concord Repatriation General Hospital - Medical Oncology Clinical Trials Unit

🇦🇺

Concord, New South Wales, Australia

Calvary Mater Hospital Newcastle

🇦🇺

Waratah, New South Wales, Australia

University of the Sunshine Coast

🇦🇺

Buderim, Australia

UZ Leuven Gasthuisberg - Pneumology Department

🇧🇪

Leuven, Vlaams-Brabant, Belgium

AZ Delta | Clinical Trial Center - Pneumology

🇧🇪

Roeselare, West-Flanders, Belgium

Antwerp University Hospital | Oncology Department

🇧🇪

Antwerpen, Belgium

Rede DoR Recife - PE

🇧🇷

Recife, Pernambuco, Brazil

Liga Norte Riograndense Contra o Cancer | Centro de Pesquisa Clínica

🇧🇷

Natal, Rio Grande Do Norte, Brazil

Irmandade Santa Casa de Misericordia de Porto Alegre | Oncology

🇧🇷

Porto Alegre, Rio Grande Do Sul, Brazil

Centro de Pesquisa da Clínica de Oncologia Reichow

🇧🇷

Blumenau, Santa Catarina, Brazil

Fundacao Pio XII - Hospital de Cancer de Barretos

🇧🇷

Barretos, Sao Paulo, Brazil

Hospital de Base | Integrated Research Center

🇧🇷

São José do Rio Preto, Sao Paulo, Brazil

NAIC - Instituto do Cancer

🇧🇷

Bauru, Brazil

Hospital Sirio-Libanes (HSL) - Centro de Oncologia - Brasilia

🇧🇷

Brasilia, Brazil

Pronutrir Fortaleza - CE

🇧🇷

Fortaleza, Brazil

Hospital Sirio Libanes

🇧🇷

Sao Paulo, Brazil

A Beneficencia Portuguesa de Sao Paulo - Hospital BP Mirante

🇧🇷

Sao Paulo, Brazil

Centro Paulista de Oncologia (CPO) - Sao Paulo - Faria Lima

🇧🇷

Sao Paulo, Brazil

MHAT Uni Hospital

🇧🇬

Panagyurishte, Pazardzhik, Bulgaria

MHAT "Heart and brain" Pleven

🇧🇬

Pleven, Bulgaria

Complex Oncology Center - Plovdiv EOOD

🇧🇬

Plovdiv, Bulgaria

MHAT Park Hospital EOOD

🇧🇬

Plovdiv, Bulgaria

Multiprofile Hospital for Active Treatment "Sveta Sofia"

🇧🇬

Sofia, Bulgaria

MHAT Serdika

🇧🇬

Sofia, Bulgaria

MHAT Sofiamed

🇧🇬

Sofia, Bulgaria

Princess Margaret Cancer Centre - University Health Network - Department of Medical Oncology and Hematology

🇨🇦

Toronto, Ontario, Canada

Jewish General Hospital - Department of Pulmonary Oncology

🇨🇦

Montreal, Quebec, Canada

BC Cancer - Vancouver

🇨🇦

Vancouver, Canada

Beijing Cancer Hospital

🇨🇳

Beijing, Beijing, China

Beijing Hospital

🇨🇳

Beijing, Beijing, China

Fujian Cancer Hospital

🇨🇳

Fuzhou, Fujian, China

Harbin Medical University Cancer Hospital

🇨🇳

Harbin, Heilongjiang, China

Union Hospi, Tongji Med College, Huazhong Univ. Scien&Tech

🇨🇳

Wuhan, Hubei, China

Hubei Cancer Hospital

🇨🇳

Wuhan, Hubei, China

Hunan Cancer Hospital

🇨🇳

Changsha, Hunan, China

NJ Drum Tower Hospital, the Affil Hos of NJ Univ Med School

🇨🇳

Nanjing, Jiangsu, China

Jilin Cancer Hospital

🇨🇳

Changchun, Jilin, China

Shanghai Chest Hospital, Shanghai Jiaotong University

🇨🇳

Shanghai, Shanghai, China

West China Hospital Sichuan University

🇨🇳

Chengdu, Sichuan, China

Sir Run Run Shaw Hospital, Zhejiang Univ. School of Medicine

🇨🇳

Hangzhou, Zhejiang, China

Zhejiang Cancer Hospital

🇨🇳

Hangzhou, Zhejiang, China

Zhejiang University School of Medicine - Taizhou Hospital of Zhejiang Province

🇨🇳

Taizhou, Zhejiang, China

Cancer Hospital, Chinese Academy of Medical Sciences

🇨🇳

Beijing, China

The People's Liberation Army General Hospital (Beijing 301 Hospital)

🇨🇳

Beijing, China

Beijing chest hospital, Capital Medical University

🇨🇳

Beijing, China

University of Electronic Science & Technology of China - Sichuan Cancer Hospital & Institute (Sichuan Provincial Tumor Hospital)

🇨🇳

Chengdu, China

Guangzhou Medical University - The First Affiliated Hospital

🇨🇳

Guangzhou, China

Shandong University - Shandong Cancer Hospital

🇨🇳

Jinan, China

LinYi Cancer Hospital (Linyi Tumor Hospital)

🇨🇳

Linyi, China

Jiangsu Provincial People's Hospital - The First Affiliated Hospital of Nanjing Medical University

🇨🇳

Nanjing, China

Guangxi Medical University (GXMU) - Affiliated Tumor Hospital

🇨🇳

Nanning, China

Fudan University - Zhongshan Hospital

🇨🇳

Shanghai, China

Xiamen University - The First Affiliated Hospital

🇨🇳

Xiamen, China

Krajská nemocnice T. Bati - Pneumoonkologická a klinická onkologie

🇨🇿

Zlin, Zlinsky Kraj, Czechia

Masarykova Univerzita - Masarykuv Onkologicky Ustav (MOU) - Klinika Komplexni Onkologicke Pece (KKOP)

🇨🇿

Brno, Czechia

Nemocnice AGEL Nový Jicín a.s. - Oddelení radioterapie a onkologie

🇨🇿

Nový Jicín, Czechia

Fakultní Nemocnice Olomouc - Klinika plicních nemocí a tuberkulózy

🇨🇿

Olomouc, Czechia

Vitkovicka nemocnice a.s.

🇨🇿

Ostrava, Czechia

Aalborg University hospital - oncology department

🇩🇰

Aalborg, Denmark

Aarhus Universitetshospital

🇩🇰

Aarhus N, Denmark

Rigshospitalet - Kræftbehandling

🇩🇰

Copenhagen OE, Denmark

Regionshospitalet Gødstrup - Medicinsk afdeling

🇩🇰

Herning, Denmark

Odense University Hospital - Oncology Department

🇩🇰

Odense C, Denmark

Turun yliopistollinen keskussairaala

🇫🇮

Turku, Finland

Hopital La Cavale Blanche - CHU de Brest - institut de cancerologie et d'imagerie

🇫🇷

Brest, France

Institut Coeur Poumon CHRU Lille - Pole Cardio-vasculaire et pulmonaire

🇫🇷

Lille, France

Centre Hospitalier Michallon Grenoble - Service pneumologie

🇫🇷

La Tronche, France

hopital Lyon sud HCL - Pneumologie aigue specialisee et cancerologie thoracique

🇫🇷

Pierre Bénite, France

Centre Hospitalier Universitaire de Limoges - unite oncologie thoracique

🇫🇷

Limoges, France

hopital Arnaud de Villeneuve CHU Montpellier - service oncologie thoracique

🇫🇷

Montpellier, France

hopital Emile Muller - Service Pneumologie

🇫🇷

Mulhouse, France

hopital cochin APHP - service de pneumologie

🇫🇷

Paris, France

Institut Curie - Paris - Oncologie medicale

🇫🇷

Paris, France

CHU de Rouen - Hopital Charles Nicolle - Service de Pneumologie

🇫🇷

Rouen, France

Universitaetsklinikum Giessen und Marburg - Medizinische Klinik IV Organonkologie

🇩🇪

Giessen, Hessen, Germany

Kliniken der Stadt Köln gGmbH - Krankenhaus Merheim - Lungenklinik

🇩🇪

Köln, Nordrhein-Westfalen, Germany

Universitaetsklinikum Essen - Innere Klinik (Tumorforschung)

🇩🇪

Essen, North Rhine-Westphalia, Germany

Charité Universitätsmedizin Berlin CBF - Med. Klinik mit Schwerpunkt Hämatologie, Onkologie und Tumorimmunologie

🇩🇪

Berlin, Germany

Universitätsklinikum Frankfurt - Medizinische Klinik II, Hämatologie und Onkologie

🇩🇪

Frankfurt, Germany

Lungenklinik Hemer, Thorakale Onkologie und onkologische Palliativmedizin

🇩🇪

Hemer, Germany

Klinikum Nürnberg - Klinik für Innere Medizin 3, Schwerpunkt Pneumologie (Lungenheilkunde)

🇩🇪

Nürnberg, Germany

Robert Bosch Krankenhaus - Haematologie, Onkologie und Palliativmedizin

🇩🇪

Stuttgart, Germany

University of Athens Medical School-Sotiria General Hospital - 3rd Dept of Medicine & Medical Oncology

🇬🇷

Athens, Greece

University of Athens Medical School- Alexandra General Hospital of Athens

🇬🇷

Athens, Greece

University General Hospital ATTIKON, Department of Internal Medicine IV

🇬🇷

Chaidari, Greece

University General Hospital of Athens "ATTIKON"

🇬🇷

Chaidari, Greece

University General Hospital of Larissa

🇬🇷

Larissa, Greece

Metropolitan Hospital- 4th Oncology Clinic

🇬🇷

Piraeus, Greece

Bioclinic Thessaloniki

🇬🇷

Thessaloniki, Greece

PAPANIKOLAOU General Hospital of Thessaloniki

🇬🇷

Thessaloniki, Greece

Prince of Wales Hospital

🇭🇰

Hong Kong, Hong Kong

Queen Mary Hospital

🇭🇰

Hong Kong, Hong Kong

Queen Elizabeth Hospital Hong Kong

🇭🇰

Hong Kong, Hong Kong

Hong Kong United Oncology Centre

🇭🇰

Kowloon, Hong Kong

Budapesti Uzsoki Utcai Korhaz - Tüdogyógyászati Osztály

🇭🇺

Budapest, Hungary

Komarom-Esztergom Varmegyei Szent Borbala Korhaz

🇭🇺

Tatabanya, Hungary

Assuta Ashdod Public Hospital (R.A)

🇮🇱

Ashdod, Israel

Soroka Medical Center- Legacy Heritage Cancer Center

🇮🇱

Be'er Sheva, Israel

Shaare Zedek Medical Center (SZMC)

🇮🇱

Jerusalem, Israel

Tel-Aviv Sourasky Medical Center

🇮🇱

Tel Aviv, Israel

AORN San Giuseppe Moscati Avellino - U.O.C. Oncologia Medica

🇮🇹

Avellino, Campania, Italy

Azienda Ospedaliero-Universitaria Di Bologna IRCCS_Policlinico Sant'Orsola - UOC Oncologia Medica

🇮🇹

Bologna, Emilia-Romagna, Italy

Istituto Romagnolo Per Lo Studio Dei Tumori Dino Amadori IRST S.r.l. - GDP Toracica

🇮🇹

Meldola, Emilia-Romagna, Italy

Centro di Riferimento Oncologico di Aviano - Oncologia Medica e dei Tumori Immuno-Correlati

🇮🇹

Aviano, Friuli-Venezia Giulia, Italy

I.F.O. Istituti Fisioterapici Ospitalieri_Ospedale Regina Elena -- Oncologia Medica 2

🇮🇹

Roma, Lazio, Italy

Fondazione Policlinico Universitario Agostino Gemelli IRCCS - UOSD Oncologia Toraco-Polmonare

🇮🇹

Roma, Lazio, Italy

Fondazione IRCCS Istituto Nazionale dei Tumori - S. C. Oncologia Medica 1

🇮🇹

Milano, Lombardia, Italy

Istituto Europeo di Oncologia s.r.l - Oncologia Toracica

🇮🇹

Milano, Lombardia, Italy

Humanitas Mirasole S.p.A. - Oncologia Medica ed Ematologia

🇮🇹

Rozzano, Lombardia, Italy

Azienda Ospedaliero-Universitaria San Luigi Gonzaga - Oncologia Medica

🇮🇹

Orbassano, Piemonte, Italy

Istituto Oncologico Veneto_Padova - UOC Oncologia 2

🇮🇹

Padova, Veneto, Italy

Careggi University Hospital - Oncologia Clinica

🇮🇹

Firenze, Italy

Ospedale Vito Fazzi Lecce - Oncologia

🇮🇹

Lecce, Italy

Ospedale San Raffaele s.r.l. - Oncologia Medica

🇮🇹

Milano, Italy

Azienda Ospedaliera Ospedali Riuniti Villa Sofia Cervello - Oncologia Medica

🇮🇹

Palermo, Italy

National Hospital Organization Nagoya Medical Center

🇯🇵

Nagoya, Aichi, Japan

National Cancer Center Hospital East

🇯🇵

Kashiwa, Chiba, Japan

Hokkaido University Hospital

🇯🇵

Sapporo, Hokkaido, Japan

National Hospital Organization Himeji Medical Center

🇯🇵

Himeji, Hyogo, Japan

Kobe University Hospital

🇯🇵

Kobe, Hyogo, Japan

Kitasato University Hospital

🇯🇵

Sagamihara, Kanagawa, Japan

Sendai Kousei Hospital

🇯🇵

Sendai, Miyagi, Japan

Kansai Medical University Hospital

🇯🇵

Hirakata, Osaka, Japan

Kindai University Hospital

🇯🇵

Osakasayama, Osaka, Japan

Saitama Cancer Center

🇯🇵

Kitaadachi-gun, Saitama, Japan

Nippon Medical School - Nippon Medical School Hospital - Cancer Center

🇯🇵

Bunkyo-ku, Tokyo, Japan

Tottori University Hospital

🇯🇵

Yonago, Tottori, Japan

National Hospital Organization-Yamaguchi-Ube Medical Center (Sanyo Hospital)

🇯🇵

Ube, Yamaguchi, Japan

National Hospital Organization Kyushu Medical Center

🇯🇵

Fukuoka, Japan

Niigata Cancer Center Hospital

🇯🇵

Niigata, Japan

Osaka International Cancer Institute

🇯🇵

Osaka, Japan

Chungbuk National University Hospital

🇰🇷

Cheongju-si, Chungcheongbugdo, Korea, Republic of

Gyeongsang National University Hospital

🇰🇷

Jinju-si, Gyeongsangnam-do, Korea, Republic of

Pusan National University Yangsan Hospital

🇰🇷

Yangsan-si, Gyeongsangnamdo, Korea, Republic of

Severance Hospital, Yonsei University Health System

🇰🇷

Seoul, Seoul Teugbyeolsi, Korea, Republic of

Seoul National University Hospital

🇰🇷

Seoul, Seoul Teugbyeolsi, Korea, Republic of

Chonnam National University Hwasun Hospital

🇰🇷

Hwasun Gun, Korea, Republic of

Samsung Medical Center

🇰🇷

Seoul, Korea, Republic of

Sunway Medical Centre

🇲🇾

Subang Jaya, Selangor, Malaysia

University Hospital Kebangsaan Malaysia

🇲🇾

Cheras, Malaysia

University Malaya Medical Centre

🇲🇾

Kuala Lumpur, Malaysia

Sunway Medical Centre Penang

🇲🇾

Perai, Malaysia

Beacon Hospital

🇲🇾

Petaling Jaya, Selangor, Malaysia

Columbia Asia Hospital Bukit Rimau

🇲🇾

Shah Alam, Malaysia

Instituto Nacional de Cancerología

🇲🇽

México, Distrito Federal, Mexico

Oncare Viaducto Nápoles

🇲🇽

Cdmx, Mexico

Oncología Integral Satélite

🇲🇽

Naucalpan, Mexico

Clinica Integral Internacional de Oncologia S. de R.L. de C.V.

🇲🇽

Puebla, Mexico

ONCARE Treatment Center

🇲🇽

San Pedro Garza García, Mexico

Nederlands Kanker Instituut

🇳🇱

Amsterdam, Netherlands

Radboud University Medical Center | Afdeling Interne Geneeskunde

🇳🇱

Nijmegen, Netherlands

Narodowy Instytut Onkologii-im. Marii Sklodowskiej-Curie Panstwowy Instytut Badawczy - Nowotworow Pluca i Klatki Piersiowej

🇵🇱

Warsaw, Mazowieckie, Poland

Uniwersytecki Szpital Kliniczny w Bialymstoku

🇵🇱

Bialystok, Poland

Swietokrzyskie Centrum Onkologii

🇵🇱

Kielce, Poland

SP ZOZ USK im. WAM UM w Lodzi - Centralny Szpital Weteranow

🇵🇱

Lodz, Poland

Mazowieckie Centrum Leczenia Chorob Pluc i Gruzlicy w Otwocku

🇵🇱

Otwock, Poland

Wielkopolskie Centrum Pulmonologii i Torakochirurgii

🇵🇱

Poznan, Poland

Dolnoslaskie Centrum Onkologii, Pulmonologii i Hematologii

🇵🇱

Wroclaw, Poland

Hospital Pedro Hispano | Clinical Research Center

🇵🇹

Matosinhos, Porto, Portugal

Fundacao Champalimaud | Centro Clinico Champalimaud - Unidade Investigacao Clinica

🇵🇹

Lisboa, Portugal

CHULN - Hospital Pulido Valente

🇵🇹

Lisboa, Portugal

IPO Porto

🇵🇹

Porto, Portugal

Radiotherapy Center Cluj SRL

🇷🇴

Flore?ti, Comuna Floresti, Romania

Institutul Oncologic Prof. Dr. Alexandru Trestioreanu (IOB); Oncologie Medicala II

🇷🇴

Bucuresti, Romania

Spitalul Clinic Coltea

🇷🇴

Bucuresti, Romania

Hospital General Universitario Gregorio Maranon | Oncologia

🇪🇸

Madrid, Spain

CardioMed S.R.L.

🇷🇴

Cluj-Napoca, Romania

Institutul Oncologic Prof. Dr. Ion Chiricuta

🇷🇴

Cluj-Napoca, Romania

Sc Oncolab Srl

🇷🇴

Craiova, Romania

Centrul de Oncologie Sfantul Nectarie

🇷🇴

Craiova, Romania

S.C Ovidius Clinical Hospital SRL - Oncology Department

🇷🇴

Ovidiu, Romania

Oncocenter

🇷🇴

Timisoara, Romania

Raffles Cancer Centre

🇸🇬

Singapore, Singapore

OncoCare Cancer Centre | Gleneagles Medical Centre

🇸🇬

Singapore, Singapore

Tan Tock Seng Hospital

🇸🇬

Singapore, Singapore

Curie Oncology | Farrer

🇸🇬

Singapore, Singapore

POKO Poprad s.r.o.

🇸🇰

Poprad, Slovakia

Fakultna nemocnica Trnava

🇸🇰

Trnava, Slovakia

Hospital Universitario Clinica Puerta de Hierro

🇪🇸

Majadahonda, Madrid, Spain

Complejo Hospitalario Universitario A Coruna (CHUAC)

🇪🇸

A Coruna, Spain

Institut Catala d'Oncologia (ICO) - Hospital Universitari Germans Trias i Pujol (HUGTP) Location

🇪🇸

Badalona, Spain

Hospital Quiron Dexeus

🇪🇸

Barcelona, Spain

Ciutat Sanitaria i Universitaria de la Vall d'Hebron

🇪🇸

Barcelona, Spain

Fundacion Instituto Valenciano de Oncologia (IVO

🇪🇸

Valencia, Spain

Hospital Universitari i Politecnic La Fe | Oncologia

🇪🇸

Valencia, Spain

Skåne University Hospital

🇸🇪

Lund, Sweden

Norrland University Hospital - Cancercentrum

🇸🇪

Umeå, Sweden

Kantonsspital Baden

🇨🇭

Baden, Aargau, Switzerland

HFR Freiburg - Kantonsspital

🇨🇭

Fribourg, Switzerland

Kaohsiung Medical University Chung-Ho Memorial Hospital

🇨🇳

Kaohsiung City, Kaohsiung, Taiwan

National Cheng Kung University Hospital

🇨🇳

Tainan, TNN, Taiwan

Chung Shan Medical University Hospital

🇨🇳

Taichung, Taiwan

Taichung Veterans General Hospital

🇨🇳

Taichung, Taiwan

Chi-Mei Medical Center, Liouyine

🇨🇳

Tainan, Taiwan

National Taiwan University Hospital (NTUH) - Cancer Research Center

🇨🇳

Taipei, Taiwan

National Taiwan University Hospital

🇨🇳

Taipei, Taiwan

Taipei Veterans General Hospital

🇨🇳

Taipei, Taiwan

Ankara Bilkent Sehir Hastanesi

🇹🇷

Bilkent Ankara, Turkey

Marmara University Hospital

🇹🇷

Istanbul, Turkey

Ege Universitesi Tip Fakultesi

🇹🇷

Izmir, Turkey

Istanbul Medeniyet Üniversitesi Göztepe Süleyman Yalçin Sehir Hastanesi

🇹🇷

Kadikoy, Turkey

I.A.Ü. VM Medical Park Florya Hastanesi

🇹🇷

Kucukcekmece, Turkey

Sakarya Universitesi Egitim ve Arastirma Hastanesi

🇹🇷

Sakarya, Turkey

Ankara Etlik Sehir Hastanesi

🇹🇷

Yenimahalle, Turkey

Adana Sehir Egitim ve Arastirma Hastanesi

🇹🇷

Yüregir, Turkey

LLC "RDP Ukraine" - Medical Department

🇺🇦

Dnipro, Ukraine

Private Enterprise Private Production Company "Acinus", Treatment and Diagnostic Center

🇺🇦

Kropyvnytskyi, Ukraine

Kyiv City Clinical Oncology Center - Department of Chemotherapy #1

🇺🇦

Kyiv, Ukraine

Limited Liability Company "MedOffice Group Medical Center"

🇺🇦

Kyiv, Ukraine

MNCE "Uzhhorod City Multidisciplinary Clinical Hospital" -Oncology Department

🇺🇦

Uzhhorod, Ukraine

Torbay Hospital

🇬🇧

Torquay, Devon, United Kingdom

Belfast City Hospital

🇬🇧

Belfast, North Ireland, United Kingdom

Royal Surrey County Hospital

🇬🇧

Guildford, Surrey, United Kingdom

© Copyright 2025. All Rights Reserved by MedPath